Matrix Metalloproteinases/Tissue Inhibitors of Metalloproteinases
Top Cited Papers
- 2 May 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 113 (17), 2089-2096
- https://doi.org/10.1161/circulationaha.105.573865
Abstract
Background— Chronic hypertension may cause left ventricular (LV) remodeling, alterations in cardiac function, and the development of chronic heart failure (CHF). Changes in the composition of the extracellular matrix (ECM) known to occur in hypertension are believed to be causally related to these structural, functional, and clinical outcomes. However, whether the determinants of ECM composition, such as the balance between ECM proteases (matrix metalloproteinases [MMPs]) and their tissue inhibitors [TIMPs]), are altered in hypertensive heart disease is unknown. Methods and Results— Plasma MMP-2, -9, and -13 values, TIMP-1 and -2 values, and Doppler echocardiography images were obtained for 103 subjects divided into 4 groups: (1) reference subjects (CTL) with no evidence of cardiovascular disease, (2) hypertensive (HTN) subjects with controlled blood pressure and no LV hypertrophy, (3) hypertensive subjects with controlled blood pressure and with LV hypertrophy (HTN+LVH) but no CHF, and (4) hypertensive s...Keywords
This publication has 29 references indexed in Scilit:
- Tissue inhibitor of metalloproteinse‐1 is a marker of diastolic dysfunction using tissue doppler in patients with type 2 diabetes and hypertensionEuropean Journal of Clinical Investigation, 2005
- p38 MAP kinase-mediated negative inotropic effect of HIV gp120 on cardiac myocytesAmerican Journal of Physiology-Cell Physiology, 2004
- Selective Targeting and Timing of Matrix Metalloproteinase Inhibition in Post-Myocardial Infarction RemodelingCirculation, 2003
- Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatmentJournal of Human Hypertension, 2003
- Lifetime Risk for Developing Congestive Heart FailureCirculation, 2002
- TIMP-1Hypertension, 2002
- Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension.International Journal of Cardiology, 2000
- Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study)The American Journal of Cardiology, 2000
- Structural remodeling in hypertensive heart disease and the role of hormones.Hypertension, 1994
- Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findingsThe American Journal of Cardiology, 1986